

Online Supplement table 1. Overview of selected prothrombotic genetic variants: previous association with cerebral ischemia or myocardial infarction and functionality studies

Gene symbol ¹	Variant	RefSNP ID number	Association with cerebral ischemia ²	Association with myocardial infarction ²	Evidence for functionality
F2	G20210A	rs1799963	1.44 (1.11--1.86) ³ [1]	1.25 (1.05--1.50) ^{3,4} [2]	yes [3]
F3	A(-603)G	rs1361600	no studies	1.44 (1.07--1.93) [8]	yes [14]
F5	Arg506Gln	rs6025	1.33 (1.12--1.58) ³ [1]	1.22 (1.10--1.35) ^{3,4} [2]	yes [15]
F13A1	Val34Leu	rs5985	0.58 (0.44--0.75) [4]	0.79 (0.66--0.93) ³ [9]	yes [16]
F13A1	Tyr204Phe	rs3024477	no association [5]	no association [5]	yes [17]
F13A1	Pro564Leu	rs5982	no association [5]	no association [5]	yes [17]
F13B	His95Arg	rs6003	no studies	no association [10]	yes [18]
FGA	Thr312Ala	rs6050	no association [6]	no association [11]	yes [19]
FGB	G(-854)A	rs1800791	no studies	no studies	yes [20]
FGB	G(-455)A	rs1800790	2.57 (1.23--5.36) [7]	0.66 (0.44-0.99) ^{3,5} [12]	yes [20]

FGG	G7874A	rs2066861	no studies	no association [13]	yes [21]
FGG	T9340C	rs1049636	no studies	0.79 (0.64--0.98) [26]	yes [31]
FGG	G5836A	rs2066860	no studies	no association [13]	no [21]
TPA	C7351T	rs2020918	1.9 (1.01--3.6) ⁵ [22]	2.68 (1.31--5.50) [27]	yes [32]
VKORC1	T2255C	rs2359612	1.95 (1.58--2.41) [23]	no studies	yes [23]
VWF	Thr789Ala	rs1063856	3.29 (1.54--7.01) ⁵ [24]	no association [24]	yes [33]
GP1BA	T(-5)C	rs2243093	1.88 (1.28--2.76) ^{3,6} [1]	no association [2]	yes [34]
GP1BA	Thr145Met	rs6065	1.55 (1.14--2.11) ³ [1]	2.0 (1.1--3.7) [28]	yes [35]
GP6	Ser219Pro	rs1613662	no studies	6.48 (1.47--28.45) ⁵ [29]	no studies
GP6	Thr249Ala	rs2304167	no studies	2.34 (1.15--4.68) ⁶ [30]	no studies
GP6	Gln317Leu	rs1654413	no association [25]	no studies	no studies
GP6	His322Asn	rs1671152	no studies	no association [30]	no studies

¹ Description of gene symbols: F2: coagulation factor II, F3: tissue factor, F5: coagulation factor V, F13A1: coagulation factor XIII subunit A, F13B: coagulation factor XIII subunit B, FGA: fibrinogen alpha, FGB: fibrinogen beta, FGG: fibrinogen gamma, TPA: tissue plasminogen activator, VKORC1: vitamin K epoxide reductase complex-1, VWF: von Willebrand factor, GP1BA: glycoprotein 1 b-alpha, GP6: glycoprotein VI. ² Odds ratio reported in a meta-analysis or a single positive study assuming dominant inheritance (heterozygote and homozygote variant genotypes versus wild type) unless otherwise stated. ³ Odds ratio from a meta-analysis. ⁴ Co-dominant inheritance (per allele odds ratio of the variant allele). ⁵ Recessive inheritance (homozygote variant genotype versus wild type and heterozygote variant genotype). ⁶ Wild type versus heterozygote and homozygote variant genotype.

References

1. Casas JP, Hingorani AD, Bautista LE, Sharma P: Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. *Arch Neurol* 2004;61:1652--1661.
2. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J: Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. *Lancet* 2006;367:651--658.
3. Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Vetter B, Hentze MW, Kulozik AE: Increased efficiency of mRNA 3' end formation: a new genetic mechanism contributing to hereditary thrombophilia. *Nat Genet* 2001;28:389--392.
4. Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P: The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. *Blood* 2000;95:586--591.
5. Reiner AP, Frank MB, Schwartz SM, Linenberger ML, Longstreth WT, Teramura G, Rosendaal FR, Psaty BM, Siscovick DS: Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women. *Br J Haematol* 2002;116:376--382.

6. Carter AM, Catto AJ, Grant PJ: Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. *Circulation* 1999;99:2423--2426.
7. Martiskainen M, Pohjasvaara T, Mikkelsen J, Mantyla R, Kunnas T, Laippala P, Ilveskoski E, Kaste M, Karhunen PJ, Erkinjuntti T: Fibrinogen gene promoter -455 A allele as a risk factor for lacunar stroke. *Stroke* 2003;34:886--891.
8. Ott I, Koch W, von Beckerath N, de Waha R, Malawaniec A, Mehilli J, Schomig A, Kastrati A: Tissue factor promoter polymorphism -603 A/G is associated with myocardial infarction. *Atherosclerosis* 2004;177:189--191.
9. Shafey M, Anderson JL, Scarvelis D, Doucette SP, Gagnon F, Wells PS: Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. *Thromb Haemost* 2007;97:635--641.
10. Reiner AP, Heckbert SR, Vos HL, Ariens RA, Lemaitre RN, Smith NL, Lumley T, Rea TD, Hindorff LA, Schellenbaum GD, Rosendaal FR, Siscovick DS, Psaty BM: Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. *Blood* 2003;102:25--30.
11. Curran JM, Evans A, Arveiler D, Luc G, Ruidavets JB, Humphries SE, Green FR: The alpha fibrinogen T/A312 polymorphism in the ECTIM study. *Thromb Haemost* 1998;79:1057--1058.
12. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ: Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. *Circulation* 2001;104:3063--3068.
13. Uitte de Willige S, Doggen CJ, de Visser MC, Bertina RM, Rosendaal FR: Haplotypes of the fibrinogen gamma gene do not affect the risk of myocardial infarction. *J Thromb Haemost* 2006;4:474--476.
14. Reny JL, Laurendeau I, Fontana P, Bieche I, Dupont A, Remones V, Emmerich J, Vidaud M, Aiach M, Gaussem P: The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers. *Thromb Haemost* 2004;91:248--254.
15. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H., van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature* 1994;369:64--67.
16. Wartiovaara U, Mikkola H, Szoke G, Haramura G, Karpati L, Balogh I, Lassila R, Muszbek L, Palotie A: Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. *Thromb Haemost* 2000;84:595--600.

17. Anwar R, Gallivan L, Edmonds SD, Markham AF: Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. *Blood* 1999;93:897--905.
18. Komanasin N, Catto AJ, Futers TS, van Hylckama V, Rosendaal FR, Ariens RA: A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis. *J Thromb Haemost* 2005;3:2487--2496.
19. Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariens RA: Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. *Circulation* 2003;107:2326--2330.
20. van 't Hooft FM, von Bahr SJ, Silveira A, Iliadou A, Eriksson P, Hamsten A: Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. *Arterioscler Thromb Vasc Biol* 1999;19:3063--3070.
21. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM: Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. *Blood* 2005;106:4176--4183.
22. Jannes J, Hamilton-Bruce MA, Pilotto L, Smith BJ, Mullighan CG, Bardy PG, Koblar SA: Tissue plasminogen activator - 7351C/T enhancer polymorphism is a risk factor for lacunar stroke. *Stroke* 2004;35:1090--1094.
23. Wang Y, Zhang W, Zhang Y, Yang Y, Sun L, Hu S, Chen J, Zhang C, Zheng Y, Zhen Y, Sun K, Fu C, Yang T, Wang J, Sun J, Wu H, Glasgow WC, Hui R: VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). *Circulation* 2006;113:1615--1621.
24. Dai K, Gao W, Ruan C: The Sma I polymorphism in the von Willebrand factor gene associated with acute ischemic stroke. *Thromb Res* 2001;104:389--395.
25. Cole VJ, Staton JM, Eikelboom JW, Hankey GJ, Yi Q, Shen Y, Berndt MC, Baker RI: Collagen platelet receptor polymorphisms integrin alpha2beta1 C807T and GPVI Q317L and risk of ischemic stroke. *J Thromb Haemost* 2003;1:963-970
26. Mannila MN, Eriksson P, Lundman P, Samnegard A, Boquist S, Ericsson CG, Tornvall P, Hamsten A, Silveira A: Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. *Thromb Haemost* 2005;93:570--577.

27. Ladenvall P, Johansson L, Jansson JH, Jern S, Nilsson TK, Tjarnlund A, Jern C, Boman K: Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction. *Thromb Haemost* 2002;87:105--109.
28. Mikkelsen J, Perola M, Penttila A, Karhunen PJ: Platelet glycoprotein Ibalpha HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. *Circulation* 2001;104:876--880.
29. Croft SA, Samani NJ, Teare MD, Hampton KK, Steeds RP, Channer KS, Daly ME: Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction. *Circulation* 2001;104:1459--1463.
30. Takagi S, Iwai N, Baba S, Mannami T, Ono K, Tanaka C, Miyata T, Miyazaki S, Nonogi H, Goto Y: A GPVI polymorphism is a risk factor for myocardial infarction in Japanese. *Atherosclerosis* 2002;165:397--398.
31. Mannila MN, Lovely RS, Kazmierczak SC, Eriksson P, Samnegard A, Farrell DH, Hamsten A, Silveira A: Elevated plasma fibrinogen gamma' concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. *J Thromb Haemost* 2007;5:766--773.
32. Wolf AT, Medcalf RL, Jern C: The t-PA -7351C>T enhancer polymorphism decreases Sp1 and Sp3 protein binding affinity and transcriptional responsiveness to retinoic acid. *Blood* 2005;105:1060--1067.
33. Lacquemant C, Gaucher C, Delorme C, Chatellier G, Gallois Y, Rodier M, Passa P, Balkau B, Mazurier C, Marre M, Froguel P: Association between high von willebrand factor levels and the Thr789Ala vWF gene polymorphism but not with nephropathy in type I diabetes. The GENEDIAB Study Group and the DESIR Study Group. *Kidney Int* 2000;57:1437-1443.
34. Afshar-Kharghan V, Li CQ, Khoshnevis-Asl M, Lopez JA: Kozak sequence polymorphism of the glycoprotein (GP) Ibalpha gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex. *Blood* 1999;94:186--191.
35. Matsubara Y, Murata M, Hayashi T, Suzuki K, Okamura Y, Handa M, Ishihara H, Shibano T, Ikeda Y: Platelet glycoprotein Ib alpha polymorphisms affect the interaction with von Willebrand factor under flow conditions. *Br J Haematol* 2005;128:533--539.